Abstract
As more bispecific antibody therapies are approved, advanced practitioners must be aware of their unique dosing strategies, toxicity profiles, and patient monitoring and coordination requirements. At JADPRO Live 2024, presenters discussed the management of patients receiving bispecific antibodies for hematologic malignancies, highlighting step-up dosing protocols, adverse effects, and the importance of patient education and monitoring.
